CURI
CuriosityStream Inc.
CURI offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
TMUS
T-Mobile US, Inc.
TMUS has a slight edge over CURI overall, supported by stronger valuation and lower modeled downside.
CURI Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Strong |
CURI's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
TMUS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Strong |
TMUS's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
CURI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $2.86 | — |
| Current | 20x | $2.86 | — |
| Cheap | N/A | N/A | N/A |
| Fair | N/A | N/A | N/A |
| Expensive | N/A | N/A | N/A |
Historical ranges are pointers, not guarantees.
CURI has the edge over TMUS in the historical PE scenario, which offers more potential upside but is not a forecast.
TMUS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 13x | $171 | — |
| Current | 16x | $171 | — |
| Cheap | 21x | $218 | +27% |
| Fair | 26x | $274 | +60% |
| Expensive | 56x | $581 | +240% |
Historical ranges are pointers, not guarantees.
TMUS's PE is in its cheap range at 16x. If earnings grow as analysts expect, today's price would be 13x next year's earnings.
CURI Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for CURI, with profitability improving. However, they disagree widely on these estimates.
TMUS Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for TMUS, with profitability improving.
CURI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.24 | +75% |
| Q3 2026 | $0.14 | +$0.23 |
| Q2 2026 | $0.00 | +$0.09 |
| Q1 2026 | -$0.14 | $0.00 |
| Q4 2025 | -$0.11 | +$0.13 |
| Q3 2025 | -$0.09 | +$0.18 |
| Q2 2025 | -$0.09 | +$0.62 |
| Q1 2025 | -$0.14 | +$0.72 |
| Q4 2024 | -$0.24 | +$0.68 |
CURI has the edge over TMUS on earnings, with more consistent year-over-year improvement.
TMUS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.49 | +30% |
| Q3 2026 | $10.37 | -0.2% |
| Q2 2026 | $9.56 | -9.7% |
| Q1 2026 | $9.41 | -8.1% |
| Q4 2025 | $9.72 | +0.6% |
| Q3 2025 | $10.39 | +18% |
| Q2 2025 | $10.59 | +33% |
| Q1 2025 | $10.24 | +39% |
| Q4 2024 | $9.66 | +39% |
TMUS earned $10.37 per share over the past year, about the same as the year before.
CURI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.7M | +13% |
| Q2 2026 | $23.2M | +22% |
| Q1 2026 | $15.2M | +0.5% |
| Q4 2025 | $19.2M | +36% |
| Q3 2025 | $18.4M | +46% |
| Q2 2025 | $19M | +53% |
| Q1 2025 | $15.1M | +26% |
| Q4 2024 | $14.1M | -4.3% |
CURI's revenue is recovering but still below its 2021 peak: $21M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18% | +42 points |
| Q2 2026 | 39% | +37 points |
| Q1 2026 | -10% | -11 points |
| Q4 2025 | -18% | +9.9 points |
| Q3 2025 | -24% | +1.3 points |
| Q2 2025 | 2.5% | +23 points |
| Q1 2025 | 0.5% | +31 points |
| Q4 2024 | -27% | +4.8 points |
CURI's operating margin was 18% last quarter, up 42 points from the same quarter a year ago, near the top of its range since 2019.
TMUS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $23.6B | +7.4% |
| Q2 2026 | $22.8B | +7.9% |
| Q1 2026 | $23.1B | +11% |
| Q4 2025 | $24.3B | +11% |
| Q3 2025 | $22B | +8.9% |
| Q2 2025 | $21.1B | +6.9% |
| Q1 2025 | $20.9B | +6.6% |
| Q4 2024 | $21.9B | +6.8% |
TMUS's revenue has grown year over year for 10 quarters in a row: $23.6B last quarter, up 7.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 24% | +3.4 points |
| Q2 2026 | 24% | -0.6 points |
| Q1 2026 | 19% | -3.5 points |
| Q4 2025 | 15% | -5.6 points |
| Q3 2025 | 21% | -3.2 points |
| Q2 2025 | 25% | +1.3 points |
| Q1 2025 | 23% | +2.6 points |
| Q4 2024 | 21% | +4 points |
TMUS has the edge over CURI on profitability, with a higher operating margin.
CURI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.4M | +0.5% |
| Q2 2026 | -$4.2M | -249% |
| Q1 2026 | $1.2M | -34% |
| Q4 2025 | $3.9M | +30% |
| Q3 2025 | $4.4M | +94% |
| Q2 2025 | $2.8M | +27% |
| Q1 2025 | $1.8M | +177% |
| Q4 2024 | $3M | +$5.6M |
CURI has burned cash in most quarters: $5M over the past year, down 55% from the year before.
TMUS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +5.3% |
| Q2 2026 | $4.8B | +4.4% |
| Q1 2026 | $4.6B | +4.6% |
| Q4 2025 | $4.2B | +25% |
| Q3 2025 | $4.8B | +15% |
| Q2 2025 | $4.6B | +32% |
| Q1 2025 | $4.4B | +79% |
| Q4 2024 | $3.3B | +2% |
TMUS has the edge over CURI on cash flow, with more consistent year-over-year improvement.
CURI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -164K shares |
| 1 year | +4.3% | +2.5M shares |
| 3 years | +14% | +7.4M shares |
| 5 years | +26% | +12.4M shares |
| Available history | +264% | +43.9M shares |
CURI has 60M diluted shares, up 4.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $560,000 |
| Q1 2026 | $311,000 |
| Q4 2025 | — |
| Q3 2025 | — |
| Q4 2024 | $33,000 |
| Q3 2024 | $192,000 |
| Q4 2020 | — |
CURI spent $871,000 buying back its own shares over the past year.
TMUS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -10.8M shares |
| 1 year | -4.9% | -55M shares |
| 3 years | -8.8% | -103M shares |
| 5 years | -15% | -182M shares |
| Available history | +24% | +207M shares |
TMUS has the edge over CURI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $2.4B |
| Q2 2026 | $2.3B |
| Q1 2026 | $4.8B |
| Q4 2025 | $2.4B |
| Q3 2025 | $2.5B |
| Q2 2025 | $2.6B |
| Q1 2025 | $2.5B |
| Q4 2024 | $4.7B |
TMUS spent $12B buying back its own shares over the past year, down 1.7% from the year before.
CURI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.7x | Net Cash |
CURI has the edge over TMUS on leverage, with a lower net debt burden relative to earnings.
TMUS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.0x | Very low |
| Q2 2026 | 0.1x | Very low |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | 2.5x | Moderate |
| Q3 2025 | 0.1x | Very low |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | 2.4x | Moderate |
TMUS's net debt is less than a year of its operating earnings (EBITDA).
CURI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.2 | Neutral |
| Stochastic | 14.3 | Oversold |
CURI's weekly RSI is 50 (neutral) and its Stochastic is 14 (oversold).
TMUS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.9 | Neutral |
| Stochastic | 42.1 | Neutral |
TMUS's weekly RSI is 48 (neutral) and its Stochastic is 42 (neutral).
CURI PE vs Communication Services Sector
TMUS PE vs Communication Services Sector
| Metric | TMUS | Sector median | Relative |
|---|---|---|---|
| PE | 16x | 16x | Same PE |
| PE % | 1 | 26 | 25 pts below |
TMUS is trading at 16x earnings, in line with the Communication Services sector's median of 16x.
CURI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.78 | 2.9% above |
| 20 week MA | $2.75 | 4% above |
| 50 week MA | $3.07 | 6.8% below |
| 100 week MA | $3.49 | 18% below |
| 200 week MA | $2.31 | 24% above |
CURI has the edge over TMUS on trend strength, trading above more of its moving averages.
TMUS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $159.1 | 7.5% above |
| 20 week MA | $172.0 | 0.5% below |
| 50 week MA | $187.8 | 8.9% below |
| 100 week MA | $212.9 | 20% below |
| 200 week MA | $188.7 | 9.4% below |
TMUS has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 9.4% below its 200-week average.
CURI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.90 | $13.8 | +39% |
| 2021 | $13.8 | $6.44 | -53% |
| 2022 | $6.44 | $1.17 | -82% |
| 2023 | $1.17 | $0.54 | -54% |
| 2024 | $0.54 | $1.58 | +193% |
| 2025 | $1.58 | $3.83 | +142% |
| 2026 YTD | $3.83 | $2.86 | -25% |
CURI's yearly returns have swung widely, from +193% in 2024 to −82% in 2022. It's down 25% so far in 2026.
TMUS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $77.2 | $132.9 | +72% |
| 2021 | $132.9 | $119.9 | -9.8% |
| 2022 | $119.9 | $140.0 | +17% |
| 2023 | $140.0 | $160.3 | +15% |
| 2024 | $160.3 | $223.0 | +39% |
| 2025 | $223.0 | $201.0 | -9.9% |
| 2026 YTD | $201.0 | $171.0 | -15% |
TMUS has the edge over CURI on returns for 2026, with the stronger performance.